All News Nirvana Life Sciences Inc.

Equities

NIRV

CA6546521064

Market Closed - Canadian Securities Exchange Other stock markets 09:30:00 2024-07-04 am EDT			5-day change	1st Jan Change
0.01 ^CAD	0.00%		0.00%	-50.00%

Apr. 02	Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	CI
Jan. 02	Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	CI

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Apr. 02	CI
Nirvana Life Sciences Inc. Announces Receipt of First North American Production of SOSA, a Patented, WHO Approved, Herbal Treatment for Opiate Addiction	Jan. 29	NE
Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Jan. 02	CI
Nirvana Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	Nov. 01	CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Full Year Ended April 30, 2023	23-10-27	CI
Nirvana Life Sciences Inc. completed the acquisition of Medsmart Dispensary Inc.	23-07-30	CI
Nirvana Life Sciences Inc. entered into a letter of intent to acquire Medsmart Dispensary Inc. for $0.13 million.	23-06-06	CI
Nirvana Life Sciences Inc. announced that it has received funding	23-05-09	CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	23-04-03	CI
Nirvana Life Sciences Inc. Announces Resignation of Chris Hoffmeister from the Board of Directors	23-02-22	CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022	22-12-30	CI
Nirvana Life Sciences Agrees to Buy Licensed Distributor of Patented, Herbal Treatment for Opiate Addiction	22-11-21	MT
Nirvana Life Sciences Inc. announces agreement to acquire the licensed distributor of a Patented, WHO approved, herbal treatment for opiate addiction	22-11-21	AQ
Nirvana Life Sciences Inc. Appoints Sheldon Inwentash to the Company's Board of Directors	22-11-09	CI
Nirvana Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2022	22-09-29	CI
Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives	22-09-22	AQ
Nirvana Life Sciences Inc. Announces a Method for Producing MDMA that Reduces Manufacturing Time by Two Thirds	22-09-07	AQ
Nirvana Life Sciences Inc. Announces Method for Producing MDMA That Reduces Manufacturing Time by Two Thirds	22-09-07	CI
Nirvana Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	22-08-28	CI
Nirvana Life Sciences Inc. Announces Executive Changes	22-08-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Nirvana Life Sciences Inc.

Equities

NIRV

CA6546521064

All News

Filters